Scancell Holdings (GB:SCLP) has released an update.
Scancell Holdings plc, an innovator in cancer immunotherapies, has announced participation and presentations at numerous prestigious conferences from September to November 2024. The company’s presence at these events follows significant advancements in their pre-clinical and clinical development of novel treatments. Scancell aims to showcase its latest work on DNA cancer vaccines and antibody-based therapies to industry professionals and investors.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.